Yamanaka factors

Yamanaka factors are the four transcription factors, Oct4, Sox2, Klf4 and c-Myc, whose forced expression converts an ordinary differentiated cell into a pluripotent stem cell. Their identification in 2006 collapsed a problem that had required eggs, embryos and nuclear transfer into a defined set of four genes that any laboratory could introduce into skin cells. The same four are now the starting point for Epigenetic reprogramming as a rejuvenation strategy, where the goal is to apply them briefly enough that the cell is reset without being converted.

§What each factor does

Oct4, encoded by POU5F1, is the core pluripotency regulator; it is expressed in the early embryo and in embryonic stem cells, and no reprogramming cocktail has reliably dispensed with it or a close functional substitute. Sox2 binds cooperatively with Oct4 at composite motifs and helps activate the pluripotency network. Klf4 supports self-renewal, suppresses apoptosis in cells being pushed out of their identity, and cooperates with the other two at enhancers. c-Myc is not a pluripotency factor at all: it is a broadly acting driver of proliferation and chromatin opening, and it raises reprogramming efficiency largely by making the genome more permissive.

Two of the four, Klf4 and c-Myc, are proto-oncogenes. That fact shapes everything downstream, from tumour incidence in early chimeric mice to the design of every proposed therapeutic use.

§How reprogramming proceeds

Introducing the factors does not flip a switch. Most treated cells never reprogramme; success rates in the original protocols were a small fraction of one per cent, and even optimised modern methods convert a minority of cells. The cells that do succeed pass through a stochastic early phase, including a mesenchymal-to-epithelial transition in fibroblasts, followed by a more deterministic late phase in which the endogenous pluripotency network activates and the exogenous factors become dispensable.

Along the way the epigenome is rewritten. DNA methylation patterns that encoded the somatic identity are erased and replaced, X-chromosome inactivation is reversed in female cells, and telomeres are re-extended by reactivated telomerase, a point of contact with telomere biology. Age-associated methylation is erased too: a fully reprogrammed cell from an eighty-year-old donor reads as embryonic on an epigenetic clock, and its estimated Biological age by that measure is effectively zero, an observation Steve Horvath reported when he introduced the first multi-tissue clock. That observation is the origin of the rejuvenation programme, and also its central puzzle, because the same process destroys the cell's usefulness as a liver or retinal cell. Cells caught partway also shed markers of Cellular senescence, which is one reason the effect is hard to attribute to any single mechanism.

§Development history

The precondition was John Gurdon's demonstration in the early 1960s that a nucleus from a differentiated frog intestinal cell, transplanted into an enucleated egg, could support development to a tadpole. Differentiation therefore did not delete information; something in the egg cytoplasm could reset it. Somatic cell nuclear transfer, later used to produce Dolly the sheep and discussed under Human cloning, worked but required eggs and gave no account of the responsible molecules.

Kazutoshi Takahashi and Shinya Yamanaka approached the problem by assembling a list of two dozen genes enriched in embryonic stem cells, introducing all of them into mouse fibroblasts by retrovirus, and then removing them one at a time to find the minimal sufficient set. Four remained.¹ The following year the group repeated the result with human fibroblasts, and James Thomson's laboratory independently reported human iPSCs using a partly different quartet, OCT4, SOX2, NANOG and LIN28, showing that the specific four were sufficient rather than uniquely necessary.²³ The 2012 Nobel Prize in Physiology or Medicine went to Yamanaka and Gurdon.

§Variants and reduced sets

Because c-Myc is the most oncogenic member, its removal was pursued immediately. Reprogramming with Oct4, Sox2 and Klf4 alone works at lower efficiency and produced chimeric mice with fewer tumours.⁴ The three-factor combination, written OSK, is now the default in rejuvenation research, including the optic nerve work central to Partial reprogramming.

Other substitutions have been mapped extensively. Nanog, Lin28, Glis1, Esrrb and various small molecules can replace or supplement individual factors. Chemical reprogramming dispenses with transgenes entirely: cocktails of small molecules produced mouse pluripotent cells in 2013 and human ones in 2022, at the cost of long, finicky protocols.⁵ A parallel line of work skips pluripotency altogether and uses lineage-specific transcription factors to convert one somatic cell type directly into another, a strategy that avoids the tumour risk by never passing through a pluripotent state. Companies such as NewLimit apply the same logic to aging, screening transcription-factor combinations for youthful gene expression within a fixed cell identity rather than for pluripotency. Retro Biosciences has instead worked on the canonical factors themselves, reporting computationally designed variants of SOX2 and KLF4 intended to raise reprogramming efficiency; that claim was announced through press coverage rather than a peer-reviewed paper and has not been independently replicated. A third approach, Epigenome editing, targets specific loci with catalytically dead Cas9 fused to methylation-writing or -erasing domains, trading the breadth of transcription-factor reprogramming for site-level control.

§Delivery

The original retroviral vectors integrate into the genome, which makes derived lines unsuitable for clinical use. The field moved through adenovirus, piggyBac transposons, episomal plasmids, Sendai virus, and synthetic modified mRNA, the last of which leaves no genetic footprint at all.⁶ Sendai virus and episomal plasmids dominate routine iPSC derivation as of 2026.

For in vivo use the constraints invert. Reaching cells inside a living animal requires AAV or lipid nanoparticles, and the requirement shifts from "leave no trace in a cultured line" to "stop expressing on command". Doxycycline-inducible transgenes provide that control in laboratory mice and have no clinical equivalent. This is the practical reason that no partial-reprogramming therapy has entered human testing with published results as of 2026, and it is a specific instance of the delivery problem that constrains Somatic gene therapy as a whole.

Naming

"Yamanaka factors" refers to the specific four-gene set, not to reprogramming in general. Papers that use OSK, or that substitute Nanog or Glis1, are often described loosely with the same term. The distinction matters when reading claims about safety, since most of the tumour data concerns constructs containing c-Myc.

§Limitations

Reprogramming is inefficient, slow, and variable between donors and cell types. Derived lines accumulate copy-number changes and point mutations, some pre-existing in the donor cell and clonally amplified, some acquired in culture; screening for them is a standard and expensive part of any clinical-grade iPSC workflow.

The factors also do not restore everything that aging removes. Reprogramming resets methylation and telomere length but does nothing about somatic mutations, which are carried forward into every daughter cell. An iPSC line from an old donor is epigenetically young and genomically old. Whether that matters for rejuvenation applications depends on how much of aging is genomic, an unsettled question at the core of the hallmarks framework.

§Outlook

As a laboratory reagent the four factors are settled technology, used daily to make patient-derived cells for disease modelling, drug screening, Organoids, Tissue engineering and cell therapy. Well-funded programmes at Altos Labs and elsewhere are betting that the same molecules can be turned into medicines rather than reagents.

As a therapeutic input they remain unproven. The open question is not whether the factors can reset a cell but whether the reset can be stopped at a chosen point, in a chosen tissue, in a living person, without producing a tumour or a cell that has forgotten its job.

§See also

• Epigenetic reprogramming
• Partial reprogramming
• Induced pluripotent stem cells
• Shinya Yamanaka
• Epigenetic clocks
• Human cloning
• NewLimit

§References